89Bio Inc
ETNB9.230USD
+0.070+0.76%
交易中 （美东）报价延迟15分钟
1.35B总市值
亏损市盈率 TTM
关于 89Bio Inc 公司
89bio, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化治疗肝脏和心脏代谢疾病的疗法。该公司的主要候选产品 pegozafermin 是一种经过特殊设计的成纤维细胞生长因子 21 (FGF21) 糖基化聚乙二醇化类似物，正在开发用于治疗非酒精性脂肪性肝炎 (NASH) 和严重高甘油三酯血症 (SHTG)。Pegozafermin 经过设计可防止蛋白水解并降低肾脏清除率并优化其效力，从而可以使用较低的剂量/剂量。Pegozafermin 已通过用天然氨基酸取代位于激素 C 末端的位点特定位置 (173 和 176) 的两个突变而最佳构建。该公司进行了一项 I 期临床试验，以评估 pegozafermin 的安全性、耐受性和药代动力学 (PK)。
公司简介
公司代码ETNB
公司名称89Bio Inc
上市日期Nov 11, 2019
CEOMr. Rohan Palekar
员工数量93
证券类型Ordinary Share
年结日Nov 11
公司地址655 Montgomery Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94111
电话14154329270
网址https://www.89bio.com/
公司代码ETNB
上市日期Nov 11, 2019
CEOMr. Rohan Palekar
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
--
--
Dr. Derek Paul Di Rocco, Ph.D.
Dr. Derek Paul Di Rocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hank Mansbach, M.D.
Dr. Hank Mansbach, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月12日 周六
更新时间: 7月12日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
持股股东
持股股东
占比
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
27.96%
Investment Advisor
25.07%
Venture Capital
15.60%
Research Firm
2.18%
Foundation
0.79%
Individual Investor
0.62%
Bank and Trust
0.44%
Pension Fund
0.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
413
161.35M
110.53%
+5.77M
2025Q1
438
159.25M
109.27%
+2.99M
2024Q4
410
127.02M
92.80%
-4.94M
2024Q3
400
110.52M
105.30%
-20.72M
2024Q2
393
109.45M
113.05%
-19.16M
2024Q1
388
104.01M
113.08%
-21.73M
2023Q4
375
99.22M
108.37%
+5.43M
2023Q3
350
77.31M
106.51%
-14.51M
2023Q2
321
82.01M
116.66%
-275.98K
2023Q1
292
75.33M
112.27%
+21.64M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
20.46M
14.02%
+371.83K
+1.85%
Mar 31, 2025
RA Capital Management, LP
19.89M
13.62%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
14.34M
9.82%
+4.13M
+40.50%
Mar 31, 2025
Deep Track Capital LP
9.32M
6.38%
+2.84M
+43.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.03M
6.19%
+1.98M
+28.00%
Mar 31, 2025
The Vanguard Group, Inc.
7.14M
4.89%
+1.47M
+25.85%
Mar 31, 2025
Avoro Capital Advisors LLC
6.35M
4.35%
+2.25M
+54.88%
Mar 31, 2025
Citadel Advisors LLC
5.09M
3.48%
+356.98K
+7.55%
Mar 31, 2025
Pictet Asset Management Ltd.
4.20M
2.88%
+1.20M
+39.84%
Mar 31, 2025
State Street Global Advisors (US)
4.03M
2.76%
+1.09M
+36.84%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
Harbor Health Care ETF
0.65%
First Trust Innovation Leaders ETF
0.55%
SPDR S&P Biotech ETF
0.3%
iShares Micro-Cap ETF
0.28%
Inspire Small/Mid Cap ESG ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Biotechnology ETF
0.14%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.92%
Harbor Health Care ETF
占比0.65%
First Trust Innovation Leaders ETF
占比0.55%
SPDR S&P Biotech ETF
占比0.3%
iShares Micro-Cap ETF
占比0.28%
Inspire Small/Mid Cap ESG ETF
占比0.26%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.17%
Invesco Nasdaq Biotechnology ETF
占比0.16%
ProShares Ultra Nasdaq Biotechnology
占比0.16%
iShares Biotechnology ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
